Hauke Ruehs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hauke Ruehs has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Michaela Meyer
Bayer AG, Pharmacometr, Wuppertal, Germany
2 shared publications - Alexander Solms
Clinical Pharmacometrics, Bayer AG, Berlin, Germany
1 shared publication Burkert Pieske
Department of Internal Medicine and Cardiology, Charité University Medicine, Campus Virchow-Klinikum, and German Heart Center, Berlin, Germany
1 shared publicationCorina Becker
Clinical Pharmacology, Bayer AG, Wuppertal, Germany
1 shared publication- Corina Becker
Clinical Pharmacology, Bayer AG, Research & Development, Wuppertal, Germany
1 shared publication Dagmar Klein
Pharmacometrics, Bayer AG, Wuppertal, Germany
1 shared publication
Latest Publications
- Open Access
- 6 September 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (11) , 1639-1648
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches
Background and Objectives Vericiguat is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and hospitalization due to heart failure. A dedicated QTc study in patients with chronic coronary syndromes demonstrated no clinically relevant QTc effect of vericiguat for exposures across the therapeutic dose range (2.5-10 mg). Interval prolongation concentration-QTc (C-QTc) modeling was performed to complement the statistical evaluations of QTc in the dedicated QTc study. Methods Individual time-matched, baseline- and placebo-corrected Fridericia-corrected QT interval values (Delta Delta QTcF) were derived. Two approaches for Delta Delta QTcF calculation were investigated: (1) Delta Delta QTcF correction with data from a single baseline (as in the primary statistical analysis); and (2) Delta Delta QTcF correction with a modeled baseline ( considering all available individual non-treatment baselines). The Delta Delta QTcF values were related to observed vericiguat concentrations with linear mixed-effects modeling. Results For both modeling approaches, a positive relationship was found between Delta Delta QTcF and vericiguat concentration; however, the slope for the single-baseline approach was not statistically significant, whereas the slope from the modeled-baseline approach was statistically significant. The upper bound of the two-sided 90% confidence interval for model-derived QTc was < 10 ms at the highest observed exposure (745 mu g/L; investigated dose range 2.5-10 mg). Conclusion By applying a single-baseline approach and a modeled-baseline approach that integrated all available QTc data across doses to characterize the QTc prolongation potential, this study showed that vericiguat 2.5-10 mg is not associated with clinically relevant QTc effects, in line with the conclusion from the primary statistical analysis.
- 6 September 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (11) , 1639-1648
Open AccessAssessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches
Background and Objectives Vericiguat is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and hospitalization due to heart failure. A dedicated QTc study in patients with chronic coronary syndromes demonstrated no clinically relevant QTc effect of vericiguat for exposures across the therapeutic dose range (2.5-10 mg). Interval prolongation concentration-QTc (C-QTc) modeling was performed to complement the statistical evaluations of QTc in the dedicated QTc study. Methods Individual time-matched, baseline- and placebo-corrected Fridericia-corrected QT interval values (Delta Delta QTcF) were derived. Two approaches for Delta Delta QTcF calculation were investigated: (1) Delta Delta QTcF correction with data from a single baseline (as in the primary statistical analysis); and (2) Delta Delta QTcF correction with a modeled baseline ( considering all available individual non-treatment baselines). The Delta Delta QTcF values were related to observed vericiguat concentrations with linear mixed-effects modeling. Results For both modeling approaches, a positive relationship was found between Delta Delta QTcF and vericiguat concentration; however, the slope for the single-baseline approach was not statistically significant, whereas the slope from the modeled-baseline approach was statistically significant. The upper bound of the two-sided 90% confidence interval for model-derived QTc was < 10 ms at the highest observed exposure (745 mu g/L; investigated dose range 2.5-10 mg). Conclusion By applying a single-baseline approach and a modeled-baseline approach that integrated all available QTc data across doses to characterize the QTc prolongation potential, this study showed that vericiguat 2.5-10 mg is not associated with clinically relevant QTc effects, in line with the conclusion from the primary statistical analysis.
- Open Access
- 4 June 2021
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 60 (11) , 1407-1421
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Background Vericiguat, a stimulator of soluble guanylate cyclase, has been developed as a first-in-class therapy for worsening chronic heart failure in adults with left ventricular ejection fraction < 45%. Objective The objective of this article was to characterize the pharmacokinetics and pharmacokinetic variability of vericiguat combined with guideline-directed medical therapy (standard of care), and identify exposure–response relationships for safety (hemodynamics) and pharmacodynamic markers of efficacy (N-terminal pro-B-type natriuretic peptide concentration [NT-proBNP]) in patients with heart failure and left ventricular ejection fraction < 45% in the SOCRATES-REDUCED study (NCT01951625). Methods Vericiguat and NT-proBNP plasma concentrations in 454 and 432 patients in SOCRATES-REDUCED, respectively, were analyzed using nonlinear mixed-effects modeling. Results Vericiguat pharmacokinetics were well described by a one-compartment model with apparent clearance, apparent volume of distribution, and absorption rate constant. Age, bodyweight, plasma bilirubin, and creatinine clearance were identified as significant covariates on apparent clearance; sex and bodyweight on apparent volume of distribution; and bodyweight and plasma albumin level on absorption rate constant. Pharmacokinetic/pharmacodynamic analysis showed initial minor and transient effects of vericiguat on blood pressure with low clinical impact. There were no changes in heart rate following initial or repeated vericiguat administration. An exposure-dependent and time-dependent turnover pharmacokinetic/pharmacodynamic model for NT-proBNP described production and elimination rates and an demonstrated exposure-dependent reduction in [NT-proBNP] by vericiguat plus standard of care compared with placebo plus standard of care. This effect was dependent on baseline [NT-proBNP]. Conclusions Vericiguat has predictable pharmacokinetics, with no long-term effects on blood pressure in patients with heart failure and left ventricular ejection fraction < 45%. A pharmacokinetic/pharmacodynamic model described a vericiguat exposure-dependent reduction of NT-proBNP. Clinical Trial Identifier NCT01951625.
- 4 June 2021
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 60 (11) , 1407-1421
Open AccessPopulation Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Background Vericiguat, a stimulator of soluble guanylate cyclase, has been developed as a first-in-class therapy for worsening chronic heart failure in adults with left ventricular ejection fraction < 45%. Objective The objective of this article was to characterize the pharmacokinetics and pharmacokinetic variability of vericiguat combined with guideline-directed medical therapy (standard of care), and identify exposure–response relationships for safety (hemodynamics) and pharmacodynamic markers of efficacy (N-terminal pro-B-type natriuretic peptide concentration [NT-proBNP]) in patients with heart failure and left ventricular ejection fraction < 45% in the SOCRATES-REDUCED study (NCT01951625). Methods Vericiguat and NT-proBNP plasma concentrations in 454 and 432 patients in SOCRATES-REDUCED, respectively, were analyzed using nonlinear mixed-effects modeling. Results Vericiguat pharmacokinetics were well described by a one-compartment model with apparent clearance, apparent volume of distribution, and absorption rate constant. Age, bodyweight, plasma bilirubin, and creatinine clearance were identified as significant covariates on apparent clearance; sex and bodyweight on apparent volume of distribution; and bodyweight and plasma albumin level on absorption rate constant. Pharmacokinetic/pharmacodynamic analysis showed initial minor and transient effects of vericiguat on blood pressure with low clinical impact. There were no changes in heart rate following initial or repeated vericiguat administration. An exposure-dependent and time-dependent turnover pharmacokinetic/pharmacodynamic model for NT-proBNP described production and elimination rates and an demonstrated exposure-dependent reduction in [NT-proBNP] by vericiguat plus standard of care compared with placebo plus standard of care. This effect was dependent on baseline [NT-proBNP]. Conclusions Vericiguat has predictable pharmacokinetics, with no long-term effects on blood pressure in patients with heart failure and left ventricular ejection fraction < 45%. A pharmacokinetic/pharmacodynamic model described a vericiguat exposure-dependent reduction of NT-proBNP. Clinical Trial Identifier NCT01951625.